Insider sales and option exercise
Barry Ticho, Stoke Therapeutics, Inc.'s chief medical officer, sold a total of 13,147 shares of the company's common stock across multiple transactions conducted March 17 through March 19, 2026, producing proceeds of approximately $413,019, according to a Form 4 filed with the Securities and Exchange Commission.
The reported transactions show a range of prices paid by purchasers, from $31.2838 to $33.3754 per share. On March 17, two sales were recorded: 3,577 shares at a weighted average price of $32.7394 and 2,587 shares at a weighted average price of $33.3754. Activity continued on March 18 with sales of 6,100 shares at a weighted average price of $31.2838, 483 shares at $31.7888, and 103 shares at $32.8500. On March 19, Ticho sold 1,461 shares at $29.99.
Also on March 19, Ticho exercised stock options to acquire 1,365 shares of Stoke Therapeutics common stock at an exercise price of $2.19, for an aggregate exercise cost of $2,989. The filing notes those options are fully vested and exercisable and have an expiration date of December 11, 2028.
Context on the sales and holdings
The Form 4 indicates the share disposals were mandated by the issuer to meet tax withholding obligations triggered by the vesting and settlement of restricted stock units. The March 19 transaction was executed under a Rule 10b5-1 trading plan that the insider adopted on November 19, 2025. After completing these transactions, Ticho directly holds 40,702 shares of Stoke Therapeutics common stock.
Market snapshot
Stoke's common shares trade on the NASDAQ under the symbol STOK. The stock is currently trading at $33.19, up from a prior close of $31.02. The filing notes that despite a roughly 9% decline over the past week, the shares have risen about 302% over the last year.
Company valuation and analyst context
The company is described as having a market valuation of $1.99 billion. An InvestingPro Fair Value analysis characterizes Stoke as slightly overvalued. InvestingPro Tips referenced in the filing emphasize that Stoke holds more cash than debt on its balance sheet, while analysts do not expect the company to be profitable this year. The platform advertises additional ProTips and a detailed Pro Research Report for subscribers seeking deeper analysis.
Corporate developments and clinical program updates
Separately disclosed corporate decisions include a discretionary bonus of $697,125 awarded to CEO Ian F. Smith, with the company citing clinical and financial performance as the basis for the award. Smith initially stepped in as interim CEO in March 2025 and was named permanent CEO in October 2025.
On the research front, Guggenheim has initiated coverage of the company with a Buy rating, highlighting potential in Stoke's lead candidate, zorevunersen, which targets Dravet syndrome. Cantor Fitzgerald has maintained an Overweight rating as the company continues discussions with the FDA about expedited regulatory pathways. The FDA has requested further information concerning the methodology used in the BUTTERFLY trial; Stoke has stated it is prepared to provide the requested material.
However, Stoke reported a delay in the Phase 3 EMPEROR study timeline for zorevunersen. The company now expects to complete patient enrollment in the second quarter of 2026, with a data readout anticipated in mid-2027. Stoke also plans to begin a rolling New Drug Application submission in the first half of 2027.
Investor implications
The Form 4 filing and the accompanying corporate updates present a mix of insider liquidity actions tied to tax obligations, an option exercise at a deeply discounted exercise price relative to current market levels, and continuing clinical and regulatory workstreams that will shape the company's near-term milestones. The company valuation commentary and analyst coverage cited in the filing reflect external perspectives on Stoke's prospects and capital position.
Note: The article presents details from the Form 4 filing and publicly disclosed corporate information as reported.